Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK's CMA Goes After Advanz, Morningside And Alliance On Nitrofurantoin

Executive Summary

The UK’s Competition and Markets Authority has issued a statement of objections to Advanz, Morningside and wholesaler Alliance Healthcare after provisionally finding that the firms broke competition law by arranging to carve up the UK market for nitrofurantoin.

You may also be interested in...



UK’s CMA Issues £35m In Fines Over Prochlorperazine

Multiple firms have been fined a total of more than £35m by the UK’s competition regulator in connection with an alleged illegal arrangement connected with anti-nausea drug prochlorperazine that led prices to increase by 700%. But Advanz and Alliance have hit back at the decision, revealing plans to appeal.

UK’s CMA Issues £35m In Fines Over Prochlorperazine

Multiple firms have been fined a total of more than £35m by the UK’s competition regulator in connection with an alleged illegal arrangement connected with anti-nausea drug prochlorperazine that led prices to increase by 700%. But Advanz and Alliance have hit back at the decision, revealing plans to appeal.

UK’s CMA Puts Investigations On Hold

Two investigations by the UK’s Competition and Markets Authority over behaviour around prochlorperazine and nitrofurantoin have been put on hold due to the coronavirus pandemic.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel